GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NAYA Biosciences Inc (NAS:NAYA) » Definitions » Asset Turnover

NAYA (NAYA Biosciences) Asset Turnover : 0.08 (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is NAYA Biosciences Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. NAYA Biosciences's Revenue for the three months ended in Sep. 2024 was $1.43 Mil. NAYA Biosciences's Total Assets for the quarter that ended in Sep. 2024 was $17.53 Mil. Therefore, NAYA Biosciences's Asset Turnover for the quarter that ended in Sep. 2024 was 0.08.

Asset Turnover is linked to ROE % through Du Pont Formula. NAYA Biosciences's annualized ROE % for the quarter that ended in Sep. 2024 was -973.01%. It is also linked to ROA % through Du Pont Formula. NAYA Biosciences's annualized ROA % for the quarter that ended in Sep. 2024 was -37.23%.


NAYA Biosciences Asset Turnover Historical Data

The historical data trend for NAYA Biosciences's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NAYA Biosciences Asset Turnover Chart

NAYA Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.15 0.16 0.39 0.12 0.27

NAYA Biosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.07 0.09 0.10 0.08

Competitive Comparison of NAYA Biosciences's Asset Turnover

For the Biotechnology subindustry, NAYA Biosciences's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NAYA Biosciences's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NAYA Biosciences's Asset Turnover distribution charts can be found below:

* The bar in red indicates where NAYA Biosciences's Asset Turnover falls into.


;
;

NAYA Biosciences Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

NAYA Biosciences's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=3.021/( (3.71+18.506)/ 2 )
=3.021/11.108
=0.27

NAYA Biosciences's Asset Turnover for the quarter that ended in Sep. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Sep. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Sep. 2024 ))/ count )
=1.433/( (18.032+17.019)/ 2 )
=1.433/17.5255
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


NAYA Biosciences  (NAS:NAYA) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

NAYA Biosciences's annulized ROE % for the quarter that ended in Sep. 2024 is

ROE %**(Q: Sep. 2024 )
=Net Income/Total Stockholders Equity
=-6.524/0.6705
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-6.524 / 5.732)*(5.732 / 17.5255)*(17.5255/ 0.6705)
=Net Margin %*Asset Turnover*Equity Multiplier
=-113.82 %*0.3271*26.138
=ROA %*Equity Multiplier
=-37.23 %*26.138
=-973.01 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

NAYA Biosciences's annulized ROA % for the quarter that ended in Sep. 2024 is

ROA %(Q: Sep. 2024 )
=Net Income/Total Assets
=-6.524/17.5255
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-6.524 / 5.732)*(5.732 / 17.5255)
=Net Margin %*Asset Turnover
=-113.82 %*0.3271
=-37.23 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) net income data. The Revenue data used here is four times the quarterly (Sep. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


NAYA Biosciences Asset Turnover Related Terms

Thank you for viewing the detailed overview of NAYA Biosciences's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


NAYA Biosciences Business Description

Traded in Other Exchanges
N/A
Address
5582 Broadcast Court, Sarasota, FL, USA, 34240
NAYA Biosciences operates a healthcare services fertility business as well as expand its focus to the development of first-in-class clinical-stage assets in oncology and autoimmune diseases.
Executives
Trent D Davis director 811 SW NAITO PARKWAY, SUITE 200, PORTLAND OR 97204
Matthew K Szot director 802 NORTH DOUTY STREET, HANFORD CA 93230
Steve Shum director 9025 SW HILLMAN COURT, SUITE 3126, WILSONVILLE OR 97070
Andrea Goren officer: Chief Financial Officer 110 EAST 59TH STREET, SUITE 1901, NEW YORK NY 10022
Barbara Ryan director 22 CAVRAY ROAD, NORWALK CT 06855
Michael Jos. Campbell director 61 SOUTH HILLS DRIVE, BEDFORD NH 03110
Rebecca Messina director 5582 BROADCAST COURT, SARASOTA FL 34240
Jeffrey Segal director INVO BIOSCIENCE, INC., 5582 BROADCAST COURT, SARASOTA FL 34240
Awm Investment Company, Inc. 10 percent owner 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022
Kevin Doody director, officer: Medical Director 1109 SOMERSET BLVD, COLLEYVILLE TX 76034
Debra Robbins Hoopes officer: Acting CFO and PFO 1 MORTON DR., SUITE 200, CHARLOTTESVILLE VA 22903
Claude Ranoux 10 percent owner 8 CHESTNUT STREET, WINCHESTER MA 01890
Kathleen T Karloff director, officer: CEO/Chairman 109 BEACON STREET UNIT 5, BOSTON MA 02116
Bowdring Robert Joseph Jr officer: Chief Financial Officer 92 GOULD STREET, WAKEFIELD MA 01880